EC Approves Itvisma Gene Therapy for SMA 2+
EC approves Itvisma SMA gene therapy adults and older children, extending one-time onasemnogene delivery beyond the infant Zolgensma setting. Novartis said on 2 July 2026 that the Commission authorised Itvisma for 5q SMA from age two upward.
Contents9 sections
Key Takeaways
- EC approved Itvisma for 5q SMA with bi-allelic SMN1 mutation in patients ≥2 years.
- Positioned as the first EU gene replacement therapy for this broad older population.
- STEER: +2.39 HFMSE points with 52-week sustained effect (company).
- One-time fixed intrathecal AAV9 dose; liver-enzyme monitoring remains central.
Itvisma EC approval at a glance
| Field | Detail |
|---|---|
| Product | Itvisma (onasemnogene abeparvovec) |
| Company | Novartis |
| Regulator | European Commission marketing authorisation |
| Date announced | 2 July 2026 |
| Population | 5q SMA, bi-allelic SMN1 mutation, ages ≥2 years |
| Modality | One-time fixed intrathecal AAV9 gene therapy |
| Key evidence | STEER (registrational); STRENGTH; STRONG |
What was approved?
Novartis said Itvisma becomes the first and only gene replacement therapy currently approved in the EU for this broad older SMA cohort, complementing intravenous onasemnogene use in younger patients under the Zolgensma franchise. The product delivers a functional SMN1 gene copy via AAV9 with a single intrathecal injection.
EMA's earlier positive CHMP/CAT path is recorded on EMA's Itvisma EPAR page. Novartis later confirmed the Commission authorisation in its 21 July GlobeNewswire Q2 2026 results release, describing Itvisma as the first and only gene replacement therapy available for this broad population. Peer-reviewed STEER and STRENGTH results were published in Nature Medicine.
What efficacy was cited?
- STEER: statistically significant 2.39-point HFMSE improvement, sustained to 52 weeks
- STRENGTH / STRONG: supportive benefit in treatment-naïve and previously treated patients (company)
- Common AEs: upper respiratory infection, pyrexia, vomiting, headache, raised hepatic enzymes
SMA trial registrations and protocols can be searched on ClinicalTrials.gov. Centres experienced with AAV gene therapy will still need local governance for intrathecal delivery, AAV serology policies, and corticosteroid / liver monitoring protocols as specified in the final SmPC.
Why does age expansion matter?
Many adolescents and adults with SMA have relied on chronically dosed SMN2-splicing or survival-motor-neuron–enhancing medicines. A one-time gene replacement option changes counselling about durability, re-dosing impossibility, and how prior SMN therapies interact with eligibility. Together with infant IV therapy, Novartis argued Europe now has gene-replacement coverage from newborns through adults — subject to each country's funding rules.
Access will hinge on HTA judgments about HFMSE gains versus cost, manufacturing slot capacity, and whether previously treated patients qualify under national criteria.
What remains uncertain?
Long-term motor durability beyond 52 weeks, AAV antibody exclusion rates, and real-world hepatic safety will shape uptake. National reimbursement timelines after EC authorisation often differ widely. Cross-label confusion with Zolgensma dosing and age bands must be avoided in clinic protocols.
Related NovaPharma coverage
- EMA positive opinion Itvisma onasemnogene
- EMA Review of Apitegromab in Spinal SMA Delayed
- CHMP July 2026: 12 New Medicines Recommended
Frequently Asked Questions
What did the European Commission approve for Itvisma?
On 2 July 2026, Novartis said the European Commission approved Itvisma (onasemnogene abeparvovec) for children two years and older, teens and adults with 5q spinal muscular atrophy caused by a bi-allelic SMN1 mutation. The company called it the first gene replacement therapy approved in the EU for this broad older SMA population.
What clinical data supported approval?
Novartis said approval rests on the registrational STEER study plus supportive STRENGTH and STRONG studies. In STEER, Itvisma showed a statistically significant 2.39-point improvement on the Hammersmith Functional Motor Scale–Expanded with effects sustained over 52 weeks.
How is Itvisma administered?
Itvisma is an AAV9-based gene therapy given as a one-time fixed intrathecal dose that does not require age- or weight-based adjustment, according to the company. Common side effects cited include upper respiratory infection, fever, vomiting, headache and increased hepatic enzymes.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Itvisma.
Unlock full calendar →Novartis pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- FDA CBER Patient Listening Meeting on Gene Therapy Safety: Patient and Care Partner Perspectives — Patient and care partner perspectives inform FDA’s thinking on approved gene therapy safety and long…